Brainsway Ltd. is dedicated to the development and marketing of Deep TMS (Transcranial Magnetic Stimluation) systems
Brainsway Ltd. is dedicated to the development and marketing of Deep TMS (Transcranial Magnetic Stimluation) systems, novel, noninvasive medical device for treatment of a wide range of neurological and psychopathological disorders. In principle, any brain-related disorder that is associated with pathological activity of specific brain sites may be treated by this method. Potential applications include addiction, schizophrenia, obesity, eating disorders, Parkinson's disease, Alzheimer's disease, autism and post-traumatic stress disorder.
Our initial focus is the treatment of major depression.
The unique technology of Brainsway is based on patents filed by the National Institute of Health (NIH), and by the company. Brainsway has an exclusive license from the NIH for the patent and technology.
The company has performed clinical trials on healthy volunteers, which proved the safety of the technology, and its ability to stimulate deep brain regions. Clinical trials with patients suffering from major clinical depression and with patients suffering from schizophrenia are currently underway. All the clinical trials are being conducted in full accordance with FDA guidelines.